Merz Pharma withdraws Obagi acquisition offer

Published



German drugmaker Merz Pharma Group has ended a plan to acquire Obagi Medical Products Inc. after a competitor raised its bid to buy the dermatology products maker.

Merz said Monday it is a “disciplined buyer,” and it was withdrawing its $22-per-share cash bid for Obagi after Canadian drugmaker Valeant Pharmaceuticals raised its offer last week to $24 per share, or about $418.3 million for the company.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.